NCT03597295 · OUTCOME

Cmin of Retifanlimab

A Study of INCMGA00012 in Squamous Carcinoma of the Anal Canal Following Platinum-Based Chemotherapy (POD1UM-202) · Source last updated 2025-08-21

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEAN
Unit: mg/L
Interval / dispersion: Standard Deviation
Time frame: pre-infusion on Day 1 of Cycles 1, 2, 4, 6, and 7; 10 minutes and 4 hours post-infusion on Day 1 of Cycles 1 and 6

What was measured

Cmin was defined as the minimum observed plasma concentration over the dose interval.

Analysis population: PK Evaluable Population

Participants received retifanlimab 500 milligrams (mg) intravenously every 4 weeks (Q4W).

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Retifanlimab 500 mg	92

Source class 1

Values in mg/L · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Retifanlimab 500 mg	22.4	7.87	Not reported	Not reported	Not reported

Complete source fields

classes

denoms

description

Cmin was defined as the minimum observed plasma concentration over the dose interval.

dispersion Type

Standard Deviation

groups

param Type

MEAN

population Description

PK Evaluable Population

reporting Status

POSTED

time Frame

pre-infusion on Day 1 of Cycles 1, 2, 4, 6, and 7; 10 minutes and 4 hours post-infusion on Day 1 of Cycles 1 and 6

title

Cmin of Retifanlimab

type

SECONDARY

unit Of Measure

mg/L

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice